Cognate Bioservices, a contract development and manufacturing organization specializing in cell and cell-mediated gene therapy products, has closed its Series B funding round. No financial terms were disclosed. The investors include EW Healthcare Partners. In addition to the funding, Cognate acquired Cobra Biologics, a provider of development and manufacturing services for the plasmid DNA and viral vector.
Source: Press Release